Dry Eye Syndrome (DES), also known as keratoconjunctivitissicca (KCS), is a multi-factorial disease of the eye characterized by dryness, decreased tear production, or increased tear film evaporation. Patients with Dry Eye Syndrome (DES) experience symptoms of discomfort, such as visual disturbance and tear film instability. Middle-aged and elderly people are most commonly affected because of the high prevalence of contact lens usage, systemic drug effects, autoimmune diseases, and refractive surgeries.In the 8MM the total prevalent cases of Dry Eye Syndrome (DES)are expected to increase from 267,680,785 cases in 2016 to 286,308,974 cases in 2026, at an Annual Growth Rate (AGR) of 0.70%.
In 2026, China will have the highest number of total prevalent cases of Dry Eye Syndrome (DES) in the 8MM with 205,637,090 total prevalent cases, whereas Spain will have the fewest number of total prevalent cases with 3,488,142 total prevalent cases in 2026. In the 8MM, the diagnosed prevalent cases are expected to increase from 100,585,137 cases in 2016 to 108,896,818 cases in 2026, at an AGR of 0.83%. In 2026, China will have the highest number of diagnosed prevalent cases of DES in the 8MM, with 64,251,395 diagnosed prevalent cases, whereas Spain will have the fewest number of diagnosed prevalent cases with 1,807,984 cases.
The report "Dry Eye Syndrome: Epidemiology Forecast to 2026", provides an overview of the risk factors, comorbidities, and the global and historical epidemiological trends for Dry Eye Syndrome (DES) in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and China). The report includes a 10-year epidemiology forecast for the diagnosed prevalent and total prevalent cases of Dry Eye Syndrome (DES) (including diagnosed and undiagnosed cases).
The epidemiology forecast for Dry Eye Syndrome (DES) is supported by historical data obtained from peer-reviewed articles and population-based studies. The forecast methodology has been kept consistent across the 8MM to allow for a meaningful comparison of the forecast prevalent cases of Dry Eye Syndrome (DES) across these markets. These sources used questionnaires to assess Dry Eye Syndrome (DES) symptoms, along with various diagnostic tests like aqueous tear flow, ocular surface damage, and measurements of tear film instability, for the 8MM in this analysis.
- The Dry Eye Syndrome (DES) Epidemiology Forecast Report provides an overview of the risk factors and global trends of DES in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and China).
- This report also includes a 10-year epidemiology forecast for the diagnosed prevalent cases and total prevalent cases (both diagnosed and undiagnosed) of DES. The total prevalent cases and diagnosed prevalent cases of DES are segmented by sex, severity (mild, moderate, and severe), and age in 10-year increments (starting at ages 20-29 years and ending at ages 80 years and older).
- The Dry Eye Syndrome epidemiology forecast report is written and developed by Masters- and PhD-level epidemiologists.
- The Epidemiology Forecast Report is in-depth, high quality, transparent, and market-driven, providing expert analysis of disease trends in the 8MM.
The Dry Eye Syndrome (DES) Epidemiology Forecast report will allow you to:
- Develop business strategies by understanding the trends shaping and driving the global DES market.
- Quantify patient populations in the global DES market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for DES therapeutics in each of the markets covered.
- Understand magnitude of DES population by severity.
1.1 Table of Contents
1.3 Related Reports
1.4 Upcoming Related Reports
2. Executive Summary
2.1 Key Findings
2.2 Key Events
3.1 Report Scope
3.2 Disease Overview and Epidemiology
4. Pipeline Assessment
4.1 Pipeline Overview
4.2 Pipeline Breakdown by Region/Country
4.3 Pipeline Breakdown by Molecule Type and Target
4.4 Drug Review Designations
4.5 Products in Clinical Development
5. Clinical Trials Assessment
5.1 Clinical Trials Overview
5.2 Top Sponsors of Clinical Trials in AxSpA
5.3 Trial Breakdown by Region
5.4 Therapy Area Perspective
5.5 Enrollment Analytics
6 Commercial Assessment
6.1 Leading Marketed Products
6.2 Current & Future Players
7. Competitive Landscape Analysis (2016-2026)
7.1 Events Classification Overview
8.3 Key Events Included in the Analysis
8.4 About the Authors